Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (HROW) on November 5, 2021, regarding events occurring on November 8, 2021. The company is incorporated in Delaware and operates as a healthcare technology firm.
Key Financial Metrics
This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only specific financial figure disclosed is a one-time settlement payment of $1,500,000.
Material Changes and Events
The filing discloses the resolution of a long-standing lawsuit filed in April 2018 by Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively "NDS"). The dispute originated from a 2013 asset purchase agreement. Following a jury trial, the parties entered into a voluntary settlement agreement on November 8, 2021, resolving all claims and pending matters.
Outlook, Risks, and Management Commentary
Management estimates the settlement will result in a single one-time payment of $1,500,000 to NDS. The company states that, except for this payment, the settlement agreement is not expected to have any future material impact on revenues, cash flows, financial position, or results of operations. No forward-looking guidance or new risk factors were introduced in this specific report.
Key Facts for Investor Verification
- Settlement amount: $1,500,000 one-time payment to resolve the NDS lawsuit.
- Event date: Settlement agreement executed on November 8, 2021.
- Impact assessment: Management asserts no future material impact on financial results beyond the settlement payment.
- Legal history: The lawsuit involved claims related to a 2013 asset purchase agreement and post-termination obligations.